ArteraAI

ArteraAI is a precision medicine company dedicated to developing artificial intelligence tests for personalized cancer treatment, providing predictive and prognostic outcomes for patients with localized prostate cancer. The company's Multimodal Artificial Intelligence (MMAI) biomarker test utilizes an algorithm to evaluate digital images of patient biopsies and learns from the patient's clinical data. The AI combines this information to predict whether a patient will benefit from a specific therapy and determine their prognosis.